Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) is a published development and funding opportunity on Contexium. The donor or funder is National Institutes of Health. Project location(s): United States. Applications close on 14 Oct 2026. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of…
Opportunity overview
- Project name
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
- Donor
- National Institutes of Health
Key details
- Opportunity start date
- Opportunity end date
- Project location(s)
- United States
Summary
Frequently asked questions
What is Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) is a published development and funding opportunity on Contexium. The donor or funder is National Institutes of Health. Project location(s): United States. Applications close on 14 Oct 2026. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of…
Who is funding Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) is funded by National Institutes of Health.
When is the deadline to apply for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
The application deadline is 14 Oct 2026 00:00 (UTC).
Where will the Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) project take place?
The project location(s) are: United States.
How can I apply for Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)?
Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.